Number-needed-to-vaccinate calculations: Fallacies associated with exclusion of transmission

Vaccine

Volumn 31, Issue 6, 2013, Pages 973-978

  Tuite, Ashleigh R ^a   Fisman, David N ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Epidemiology; Herd immunity; Immunization; Mathematical model; Number needed to vaccinate

Indexed keywords

VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; DISEASE TRANSMISSION; DRUG EFFICACY; ENDEMIC DISEASE; EPIDEMIC; HEALTH PROGRAM; HERD IMMUNITY; INNATE IMMUNITY; MATHEMATICAL MODEL; PRIORITY JOURNAL; PUBLIC HEALTH; VACCINATION;

DISEASE OUTBREAKS; DISEASE TRANSMISSION, INFECTIOUS; ENDEMIC DISEASES; EPIDEMIOLOGIC METHODS; HUMANS; MODELS, THEORETICAL; VACCINATION;

EID: 84872611211     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.097     Document Type: Article

References (33)

1. Centers for Disease C and Prevention Progress toward interrupting wild poliovirus circulation in countries with reestablished transmission-Africa, 2009-2010. MMWR Morb Mortal Wkly Rep 2011, 60(March (10)):306-311.
2. Benkimoun P. Outbreak of measles in France shows no signs of abating. BMJ 2011, 342:d3161.
3. Delaporte E., Richard J.L., Wyler Lazarevic C.A., Lacour O., Girard M., Ginet C., et al. Ongoing measles outbreak, Geneva, Switzerland, January to March 2011. Euro Surveill 2011, 16(10). pii=19815. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19815.
4. Demirjian A., Levy O. Novel vaccines: bridging research, development and production. Expert Rev Vaccines 2008, 7(November (9)):1321-1324.
5. Pichichero M.E. Improving vaccine delivery using novel adjuvant systems. Hum Vaccine 2008, 4(July-August (4)):70-262.
6. Burchett H.E., Mounier-Jack S., Griffiths U.K., Mills A.J. National decision-making on adopting new vaccines: a systematic review. Health Policy Plan 2012, 27(Suppl 2):ii62-ii76. 10.1093/heapol/czr049.
7. Cook R.J., Sackett D.L. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995, 310(February (6977)):452-454.
8. Brisson M., Van de Velde N., De Wals P., Boily M.C. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ 2007, 177(August (5)):464-468.
9. Rand C.M., Szilagyi P.G., Albertin C., Auinger P. Additional health care visits needed among adolescents for human papillomavirus vaccine delivery within medical homes: a national study. Pediatrics 2007, 120(September (3)):461-466.
10. Kelly H., Carcione D., Dowse G., Effler P. Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010. Euro Surveill 2010, 15(37). pii=19661, Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19661.
11. Cools H.J., Gussekloo J., Remmerswaal J.E., Remarque E.J., Kroes A.C. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial. J Med Virol 2009, 81(May (5)):908-914.
12. Lewis E.N., Griffin M.R., Szilagyi P.G., Zhu Y., Edwards K.M., Poehling K.A. Childhood influenza: number needed to vaccinate to prevent 1 hospitalization or outpatient visit. Pediatrics 2007, 120(September (3)):467-472.
13. Skowronski D.M., Janjua N.Z., Sonfack Tsafack E.P., Ouakki M., Hoang L., De Serres G. The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization. Clin Infect Dis 2012, 54(February (3)):27-318.
14. Kelly H., Attia J., Andrews R., Heller R.F. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 2004, 22(June (17-18)):2192-2198.
15. Mooney J.D., Weir A., McMenamin J., Ritchie L.D., Macfarlane T.V., Simpson C.R., et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis 2008, 8:53.
16. Gordis L. Epidemiology 2009, Elsevier/Saunders, Philadelphia. 4th ed.
17. Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Public Health 2008, 99(September-October (5)):6-383.
18. Anderson R.M., May R.M. Infectious diseases of humans: dynamics and control 1991, Oxford University Press, Oxford.
19. Brachman P.S., Abrutyn E. Bacterial infections of humans: epidemiology and control 2009, Springer, New York, NY. 4th ed.
20. Trotter C.L., Gay N.J., Edmunds W.J. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2005, 162(July (1)):89-100.
21. Trotter C.L., Gay N.J., Edmunds W.J. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006, 134(June (3)):556-566.
22. Dushoff J., Plotkin J.B., Levin S.A., Earn D.J. Dynamical resonance can account for seasonality of influenza epidemics. Proc Natl Acad Sci USA 2004, 101(November (48)):16915-16916.
23. Orenstein W.A., Schaffner W. Lessons learned: role of influenza vaccine production, distribution, supply, and demand-what it means for the provider. Am J Med 2008, 121(July (7 Suppl. 2)):S22-S27.
24. Diekmann O., Heesterbeek J.A.P. Dynamics at the demographic time scale. Mathematical epidemiology of infectious diseases: model building, analysis and interpretation 1998, 42-62. John Wiley and Sons, Chichester, West Sussex, UK. S. Levin (Ed.).
25. Kinlin L.M., Jamieson F., Brown E.M., Brown S., Rawte P., Dolman S., et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine 2009, 27(March (11)):1735-1740.
26. Centers for Disease C and Prevention Ten great public health achievements-United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999, 48(April (12)):241-243.
27. Brisson M., Edmunds W.J. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003, 23(January-February (1)):76-82.
28. Brisson M., Edmunds W.J. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006, 26(September-October (5)):46-434.
29. Hayward A.C., Harling R., Wetten S., Johnson A.M., Munro S., Smedley J., et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ 2006, 333(December (7581)):1241.
30. Galvani A.P., Reluga T.C., Chapman G.B. Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proc Natl Acad Sci USA 2007, 104(March (13)):5692-5697.
31. Mossong J., Hens N., Jit M., Beutels P., Auranen K., Mikolajczyk R., et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008, 5(March (3)):e74.
32. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999, 5(May-June (3)):45-336.
33. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294(October (16)):2043-2051.